Posted by Michael Wonder on 02 Jun 2024
Dupixent recommended for EU approval by the CHMP to treat patients with COPD
31 May 2024 - Recommendation for adults with uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function.
The EMA’s CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease characterised by raised blood eosinophils.
